Trials / Completed
CompletedNCT00598650
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2020 | Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2008-01-22
- Last updated
- 2014-09-03
- Results posted
- 2014-09-03
Source: ClinicalTrials.gov record NCT00598650. Inclusion in this directory is not an endorsement.